Page 28 - Lupin
USFDA clears Lupin's Goa plant, closes July 2015 inspection
The Goa plant accounts for 50% of Lupin's US sales and adverse observations from FDA resulted in delayed product approvals for the company
 "USFDA clears Lupin's Goa plant, closes July 2015 inspection")
Lupin surges on receiving EIR from USFDA for Goa facility
The stock moved higher by 9% to Rs 1,698 on the NSE.
Lupin records sharpest single day gain in three months
The stock ended higher by 4.4% to Rs 1,543 on the BSE, recorded its sharpest single day gain since March 30, 2016.
Lupin gets USFDA nod for fungal infection drug
Mumbai based Lupin produces and develops a wide range of branded & generic formulations, biotechnology products and APIs globally
 "Lupin gets USFDA nod for fungal infection drug")
Lupin shares fall 2% on product recall in US
Company's US arm Lupin Pharmaceuticals Inc is initiating the recall
Lupin recalls over 54,000 vials of anti-bacterial injection in US
Anti-bacterial injection Ceftriaxone are being recalled due to violation of current good manufacturing norms
Lupin gets final USFDA nod for fungal treatment drug
Lupin further said that the company shall commence promoting the products in the US shortly
Lupin eyes 25-30 product launches in US this fiscal
Overall, between Lupin and Gavis combined, over 160 products filings are pending for approval with USFDA
 "Lupin eyes 25-30 product launches in US this fiscal")
FDA clears Lupin's Aurangabad, Mandideep plants
Earlier, both the plants had received adverse observations from the US drug regulator
Lupin tanks 9% on FDA concerns
In March, Lupin received nine adverse observations from US drug regulator at its Goa plant and the company expects resolution in the next 3-6 months
Lupin dips on USFDA concerns about Goa plant
The stock dipped almost 8% to Rs 1,525 on the BSE in early morning trade on the BSE.
Expect business to grow 20% in FY17: Vinita Gupta
Interview with CEO, Lupin
 "Expect business to grow 20% in FY17: Vinita Gupta")
Lupin Q4 net surges 47.5% to Rs 807 cr
Total revenue grew 34% to Rs 4,091 cr
 "Lupin Q4 net surges 47.5% to Rs 807 cr")
Lupin ends the year on a strong note
Diabetics products boost US growth; India, Japan, others add to Street beating performance
Lupin looks to strengthen brand, specialty business in the US
Company's CFO said launch of Methergine oral tablets will have a positive impact on Lupin's US revenues
Lupin gains on re-introducing Methergine oral tablets in US
The company has re-introduced Methergine Oral tablets 0.2mg for the management of PPH
 "Lupin gains on re-introducing Methergine oral tablets in US")
Lupin strengthens branded drug business in US
The drug, Methergine, is the only FDA approved oral uterotonic and Lupin has created of a specialised sales force to drive product sales
Lupin launches generic Femhrt tablets in US
The product is generic version of Warner Chilcott's Femhrt tablets in the same strengths, Lupin said
Lupin gains on launch of first product from GAVIS pipeline in the US
The US arm has launched Zolpidem Sublingual Tablets, 1.75mg & 3.5mg used for treatment of insomnia
Lupin launches generic insomnia drug in US
Reacting to the news, stock of Lupin was trading at Rs 1,465.30 on BSE, up 0.27% from the previous close